



Curriculum Vitae

Personal information Mohammed Alali

Work experience

1. Employer: World Health Organization
 - Start date: 062015
 - End date:
 - Position: Vaccines scientist
 - Activities: Vaccines assessment for WHO Prequalification; CMC; GMP Inspection including QC of vaccines manufacture, Regulation of Vaccines, WHO NRAs Assessment as part of Regulatory System Strengthening WHO activities
 - Country: Switzerland
2. Employer: Therapeutic Good Administration
 - Start date: 082001
 - End date: 122017
 - Position: Senior vaccines scientist _ Team leader
 - Activities: Pre and Post-Marketing Authorization; Regulation of Vaccines _ Assessment of Vaccines CMC part, QC and Vaccines testing and lot releases of vaccines for Australia (WHO contracted lab testing); Virologist (assessment of medicinal product for Viral Safety)
 - Country: Australia
3. Employer: Centre for Virus Research, Westmead Millennium Institute and Medical Research Centre
 - Start date: 061996
 - End date: 072001
 - Position: Hospital Scientist
 - Activities: In_charge of the PC3 HIV isolation laboratory and PC2 Cell Culture facility at the Centre for Virus Research, Westmead Millennium Institute and Research Centre, Westmead Hospital and University of Sydney, NSW, Australia
 - Country: Australia
4. Employer: Self-employed
 - Start date: 071984
 - End date: 011992
 - Position: Veterinary Doctor
 - Activities: Clinician _ Private clinic
 - Country: Iraq

Education and training

1. Subject: Faculty of Medicine, University of Sydney
 - Start date: 021997
 - End date: 072001
 - Qualification: PhD in Medicine/Virology
 - Organisation: PhD in Medicine/Virology Virological Characterisation and Molecular Mechanisms of Co-receptor Utilisation of Locally Isolated Human Immunodeficiency virus type 1 (HIV-1) Strains
 - Country: Australia
2. Subject: College of Veterinary Medicine & Surgery, University of Mosul
 - Start date: 101978
 - End date: 061983
 - Qualification: Bachelor of Veterinary Medicine and Surgery
 - Organisation: Veterinary Medicine and Surgery Large and small animals
 - Country: Iraq

Additional information

Publications

1. Assessing the risk of a clinically significant infection from a Microneedle Array Patch (MAP) product. Journal of the Controlled Release Society, accepted in July 2023
2. Co-author of the WHO informal consultation on revision of guidelines to assure the quality, safety and efficacy of live attenuated rotavirus vaccines, 15-17 November 2022 - Published WHO website in March 2023.
3. Co-author of the World Health Organization (WHO) Technical Review Series - Recommendations to assure the quality, safety and efficacy of typhoid conjugate vaccines no. 1030, Annex 2, Geneva, 2021
4. Co-author of the World Health Organization (WHO) Technical Review Series - Recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines (inactivated) No 1030, Annex 3, published in 2021
5. Co-author of the World Health Organization (WHO) Technical Review Series - Guidelines for evaluation of the quality, safety, and efficacy of DNA vaccines 1028, Annex 2, 2021, Geneva, Switzerland
6. Co-author of the World Health Organization (WHO) Technical Review Series "Guidelines on the quality, safety and efficacy of respiratory syncytial virus vaccines" Nov 2019.
7. Co-author of the World Health Organization (WHO) Technical Review Series (TRS) No. 910 "Guidelines on the quality, safety and efficacy of Japanese encephalitis vaccine (live, attenuated) for human use, 2012.
8. Primary author for the Standard Operating Procedures (SOPs) and Manuals used for potency testing methods of Live Viral Vaccines (i.e Varicella, Measles, Mumps, Rubella, OPV, Rotavirus & Japanese Encephalitis viruses) scheduled for the Australian Immunisation Program. TGA Internal Quality Control

documents (2001_present).

9. A human immunodeficiency virus type 1 isolate from an infected person homozygous for CCR5Delta32 exhibits dual tropism by infecting macrophages and MT2 cells via CXCR4. *J Virol* 76:3114_24, 2002.
10. Mast cells/Basophils in Human Peripheral Blood of Allergic Individuals that are HIV_1 Susceptible Due to their Surface Expression of CD4 and the Chemokine Receptors CCR3, CCR5, and CXCR4. *97 (11) Blood* 2001.
11. The level of HIV infection of macrophages is determined by interaction of viral and host cell genotypes. *J. Leuko Biol.* 2000 68 (3) 311_7.
12. Definition of the Stage of Host Cell Genetic Restriction of Replication of HIV_1 in monocytes and Monocyte-Derived Macrophages Using Twins. *J Virol*, 73(4866_4881) 1999.
13. Differential Tropism and Coreceptor Usage of Primary Isolates of Human immunodeficiency virus type1 are associated with Disease Progression. *J. Virol*, 73, 1999.
14. CCR5 Expression Correlates with Susceptibility of Maturing Monocytes to Human Immunodeficiency Virus Type1 Infection. *J. Virol*, 72: 830_836, 1998.
15. Tropism and replication of HIV_1 primary isolates involved in vertical transmission from mother to baby. (paper submitted to *Journal of Virology* in 2001 – Not finalised due to employment opportunity).
16. PhD Thesis title is "Virological Characterisation and Molecular Mechanisms of Co-receptor Utilisation of Locally Isolated Human Immunodeficiency virus type 1 (HIV-1) Strains".

Projects

Please refer to publications which indicates the type of involvements in projects and hence published internationally

Memberships

2020 - present: A member of the Scientific Committee members and experts, European Medicines Agency (EMA)
2013 Member of the International AIDS Society (IAS)
2011 Member of the Australasian Society for Virology (ASV)
2010 Member of the International Society for Vaccines (ISV)
2008 Member of the International Society for Infectious Diseases (ISID)
2007 Member of the Australian Society for Microbiology (ASM)
2000 Member of the American Society for Microbiology (ASM)

Other Relevant Information

AWARDS: 2012 "Fifteen Years Service Recognitions" Award for significant contribution to the Australian community through public service and in the particular to the health and active ageing of all Australians – Department of Health & Ageing, October 2012. 2004 Travel Grant Award from the International Vaccine Institute (IVI) to attend the 2004 KOSEF_JSPS Asian Seminar – Development of Mucosal Vaccines from Basic Research to Clinical Application, Seoul Korea 2001 The University of Sydney PhD Completion Scholarship Award for the year 2001. 2000 Travel Grant Award from the European Virology Association to attend the European Virology 2000 conference, Glasgow, Scotland from 17_21 of Sep. 2000. 1999 The Faculty of Medicine Postgraduate Travel Grant Award, to attend the 4th International Workshop on HIV, cells of Macrophage Lineage, and other Reservoirs, from 1_4th of Dec. 1999, Florence, Italy. RECOGNITIONS: 2004 _ 2009 TGA Principal Investigator for testing of Live Viral Vaccines for World Health Organization. Vaccines included Measles, Mumps, Rubella, and OPV 2004 _ 2007 Auditor within the TGA Laboratories (Microbiology and Biotechnology) 2005 _ 2012 Signatory for the Australian National Association of Testing Authorities (NATA) Assessment of Live Viral Vaccine Stream during the years 2006 _ 2015 2015_present Staff member of Vaccines Assessment Team of WHO Prequalification of Vaccines, Geneva, Switzerland